Fetal neural grafts for Huntington's disease: A prospective view
Identifieur interne : 001802 ( Istex/Curation ); précédent : 001801; suivant : 001803Fetal neural grafts for Huntington's disease: A prospective view
Auteurs : Anne-Catherine Bachoud-Lévi [France] ; Philippe Hantraye [France] ; Marc Peschanski [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-05.
English descriptors
Abstract
Intrastriatal transplantation of striatal neuroblasts from human fetuses is a promising approach for treatment of Huntington's disease, on the basis of many experimental animal studies and, most recently, pilot clinical trials. Technically, several issues remain to be resolved (e.g., the precise site of dissection of the fetal tissue; the number and location of the fetal striatal implants; or the use of immunosuppressive therapy), and await larger‐scale trials and purposely designed protocols. Further clinical data must also be obtained, and preliminary promising results must be replicated in a patient group large enough to provide conclusive results. It is important to establish (1) the amount of clinical benefit provided to the patient by the grafted cells; (2) the anticipated duration of clinical benefits; and (3) the secondary rate of decline after the benefit of the graft has been overbalanced. Evaluation of these parameters will require very long‐term follow‐up of the patients involved, over several years after grafting, before the technique can eventually be proposed widely to patients. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10117
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001802
Links to Exploration step
ISTEX:E2AD65FFE6CA6B8C1AA65A758F8EA6B20D39E170Curation
No country items
Anne-Catherine Bachoud-Lévi<affiliation><mods:affiliation>Department of Medical Neurosciences, CHU Henri‐Mondor, 94010 Créteil France</mods:affiliation><wicri:noCountry code="subField">94010 Créteil France</wicri:noCountry></affiliation>Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fetal neural grafts for Huntington's disease: A prospective view</title><author><name sortKey="Bachoud Evi, Anne Atherine" sort="Bachoud Evi, Anne Atherine" uniqKey="Bachoud Evi A" first="Anne-Catherine" last="Bachoud-Lévi">Anne-Catherine Bachoud-Lévi</name><affiliation wicri:level="1"><mods:affiliation>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil</wicri:regionArea></affiliation><affiliation><mods:affiliation>Department of Medical Neurosciences, CHU Henri‐Mondor, 94010 Créteil France</mods:affiliation><wicri:noCountry code="subField">94010 Créteil France</wicri:noCountry></affiliation></author><author><name sortKey="Hantraye, Philippe" sort="Hantraye, Philippe" uniqKey="Hantraye P" first="Philippe" last="Hantraye">Philippe Hantraye</name><affiliation wicri:level="1"><mods:affiliation>CEA‐CNRS URA 2210, Service Hospitalier Frédéric Joliot, 91401 Orsay Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA‐CNRS URA 2210, Service Hospitalier Frédéric Joliot, 91401 Orsay Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name><affiliation wicri:level="1"><mods:affiliation>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E2AD65FFE6CA6B8C1AA65A758F8EA6B20D39E170</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10117</idno><idno type="url">https://api.istex.fr/document/E2AD65FFE6CA6B8C1AA65A758F8EA6B20D39E170/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001802</idno><idno type="wicri:Area/Istex/Curation">001802</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Fetal neural grafts for Huntington's disease: A prospective view</title><author><name sortKey="Bachoud Evi, Anne Atherine" sort="Bachoud Evi, Anne Atherine" uniqKey="Bachoud Evi A" first="Anne-Catherine" last="Bachoud-Lévi">Anne-Catherine Bachoud-Lévi</name><affiliation wicri:level="1"><mods:affiliation>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil</wicri:regionArea></affiliation><affiliation><mods:affiliation>Department of Medical Neurosciences, CHU Henri‐Mondor, 94010 Créteil France</mods:affiliation><wicri:noCountry code="subField">94010 Créteil France</wicri:noCountry></affiliation></author><author><name sortKey="Hantraye, Philippe" sort="Hantraye, Philippe" uniqKey="Hantraye P" first="Philippe" last="Hantraye">Philippe Hantraye</name><affiliation wicri:level="1"><mods:affiliation>CEA‐CNRS URA 2210, Service Hospitalier Frédéric Joliot, 91401 Orsay Cedex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEA‐CNRS URA 2210, Service Hospitalier Frédéric Joliot, 91401 Orsay Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name><affiliation wicri:level="1"><mods:affiliation>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut National de la Santé et de la Recherche Médicale U 421/IM3, Faculté de Médecine, 94010 Créteil</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-05">2002-05</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="439">439</biblScope><biblScope unit="page" to="444">444</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E2AD65FFE6CA6B8C1AA65A758F8EA6B20D39E170</idno><idno type="DOI">10.1002/mds.10117</idno><idno type="ArticleID">MDS10117</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>cell therapy</term><term>clinical trial</term><term>neurodegenerative disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intrastriatal transplantation of striatal neuroblasts from human fetuses is a promising approach for treatment of Huntington's disease, on the basis of many experimental animal studies and, most recently, pilot clinical trials. Technically, several issues remain to be resolved (e.g., the precise site of dissection of the fetal tissue; the number and location of the fetal striatal implants; or the use of immunosuppressive therapy), and await larger‐scale trials and purposely designed protocols. Further clinical data must also be obtained, and preliminary promising results must be replicated in a patient group large enough to provide conclusive results. It is important to establish (1) the amount of clinical benefit provided to the patient by the grafted cells; (2) the anticipated duration of clinical benefits; and (3) the secondary rate of decline after the benefit of the graft has been overbalanced. Evaluation of these parameters will require very long‐term follow‐up of the patients involved, over several years after grafting, before the technique can eventually be proposed widely to patients. © 2002 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001802 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001802 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:E2AD65FFE6CA6B8C1AA65A758F8EA6B20D39E170
|texte= Fetal neural grafts for Huntington's disease: A prospective view
}}
| This area was generated with Dilib version V0.6.23. |  |